Full text is available at the source.
Abstract
GLP-1 receptor agonists (GLP-1RAs) show promise for Parkinson's disease (PD).
- The efficacy of GLP-1RAs in treating Parkinson's disease remains unclear.
- Safety profiles of GLP-1RAs in the context of Parkinson's disease are still under investigation.
- Further research is needed to establish comprehensive data on their effects.
Simplified